Search Results - "Smit, Hans J. M"

Birt-Hogg-Dubé syndrome in apparent primary spontaneous pneumothorax patients; results and recommendations for clinical practice by Sriram, Jincey D, van de Beek, Irma, Johannesma, Paul C, van Werkum, Michiel H, van der Wel, Tijmen J. W. T, Wessels, Elise M, Gille, Hans J. J. P, Houweling, Arjan C, Postmus, Pieter E, Smit, Hans J. M

“…Background Birt-Hogg-Dubé syndrome (BHD) is an inherited disease caused by pathogenic variants in the FLCN gene. One of the characteristics is the increased…”
Get full text

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer by Ardizzoni, Andrea, Azevedo, Sergio, Rubio-Viqueira, Belen, Rodríguez-Abreu, Delvys, Alatorre-Alexander, Jorge, Smit, Hans J M, Yu, Jinming, Syrigos, Konstantinos, Trunzer, Kerstin, Patel, Hina, Tolson, Jonathan, Cardona, Andres, Perez-Moreno, Pablo D, Newsom-Davis, Tom

“…BackgroundAtezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer…”
Get full text

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer by SMIT, Egbert F, BURGERS, Sjaak A, GROEN, Harry J. M, BIESMA, Bonne, SMIT, Hans J. M, EPPINGA, Pier, DINGEMANS, Anne-Marie C, JOERGER, Markus, SCHELLENS, Jan H, VINCENT, Andrew, VAN ZANDWIJK, Nico

“…We performed a randomized phase II trial comparing pemetrexed with pemetrexed plus carboplatin (PC) in patients experiencing relapse after platinum-based…”
Get full text

Treatment of haemothorax by Boersma, Wim G, Stigt, Jos A, Smit, Hans J.M

“…Summary Haemothorax is a problem commonly encountered in medical practice and is most frequently related to open or closed chest trauma or to invasive…”
Get full text

Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study by GROEN, Harry J. M, SIETSMA, Hannie, HILTERMANN, T. Jeroen N, VAN DEN BORNE, Ben E. E. M, SCHRAMEL, Franz M. N. H, VINCENT, Andrew, HOCHSTENBAG, Monique M. H, VAN PUTTEN, John W. G, VAN DEN BERG, Anke, DALESIO, Otilia, BIESMA, Bonne, SMIT, Hans J. M, TERMEER, Arien

“…Cyclooxygenase-2 (COX-2) protein expression in patients with non-small-cell lung cancer (NSCLC) may be not only a prognostic marker but also predictive for…”
Get full text

Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations by Westerink, Lotte, Nicolai, Jelmer L. J., Samuelsen, Carl, Smit, Hans J. M., Postmus, Pieter E., Griebsch, Ingolf, Postma, Maarten J.

“…Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that have common epidermal growth factor receptor (EGFR) mutations has…”
Get full text

Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer by Ardizzoni, Andrea, Azevedo, Sergio, Rubio-Viqueira, Belen, Rodriguez-Abreu, Delvys, Alatorre-Alexander, Jorge, Smit, Hans J M, Yu, Jinming, Syrigos, Konstantinos, Höglander, Elen, Kaul, Monika, Tolson, Jonathan, Hu, Youyou, Vollan, Hans Kristian, Newsom-Davis, Thomas

“…In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety…”
Get full text

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial by Brouns, Anita J. W. M., Hendriks, Lizza E. L., van der Noort, Vincent, van de Borne, Ben E. E. M, Schramel, Franz M. N. H., Groen, Harry J. M., Biesma, Bonne, Smit, Hans J. M., Dingemans, Anne-Marie C.

“…Introduction: Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases have cancer induced bone pain (CIBP). Methods: The NVALT-9…”
Get full text

Improving shared decision making for lung cancer treatment by developing and validating an open-source web based patient decision aid for stage I-II non-small cell lung cancer by Halilaj, Iva, Ankolekar, Anshu, Lenaers, Anouk, Chatterjee, Avishek, Oberije, Cary J G, Eppings, Lisanne, Smit, Hans J M, Hendriks, Lizza E L, Jochems, Arthur, Lieverse, Relinde I Y, van Timmeren, Janita E, Wind, Anke, Lambin, Philippe

“…The aim of this study was to develop and evaluate a proof-of-concept open-source individualized Patient Decision Aid (iPDA) with a group of patients,…”
Get full text

Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer by TIMMER-BONTE, Johanna N. H, ADANG, Eddy M. M, SMIT, Hans J. M, BIESMA, Bonne, WILSCHUT, Frank A, BOOTSMA, Gerben P, DE BOO, Theo M, TJAN-HEIJNEN, Vivianne C. G

“…Recently, a Dutch, randomized, phase III trial demonstrated that, in small-cell lung cancer patients at risk of chemotherapy-induced febrile neutropenia (FN),…”
Get full text

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study by Girard, Nicolas, Bar, Jair, Garrido, Pilar, Garassino, Marina C, McDonald, Fiona, Mornex, Françoise, Filippi, Andrea R, Smit, Hans J M, Peters, Solange, Field, John K, Christoph, Daniel C, Sibille, Anne, Fietkau, Rainer, Haakensen, Vilde D, Chouaid, Christos, Markman, Ben, Hiltermann, T Jeroen N, Taus, Alvaro, Sawyer, William, Allen, Allison, Chander, Pratibha, Licour, Muriel, Solomon, Benjamin

“…The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease…”
Get more information

Efficacy of an Autologous Blood Patch for Prolonged Air Leak: A Systematic Review by Hugen, Niek, Hekma, Edo J., Claessens, Niels J.M., Smit, Hans J.M., Reijnen, Michel M.P.J.

“…Prolonged air leak after pulmonary surgery remains a clinical challenge and sometimes needs surgical reintervention. An autologous blood patch (ABP) may…”
Get full text

Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis by Kuiper, Justine L, Hendriks, Lizza E, van der Wekken, Anthonie J, de Langen, Adrianus J, Bahce, Idris, Thunnissen, Erik, Heideman, Daniëlle A.M, Berk, Yvonne, Buijs, Ed J.M, Speel, Ernst-Jan M, Krouwels, Frans H, Smit, Hans J.M, Groen, Harry J.M, Dingemans, Anne-Marie C, Smit, Egbert F

“…Highlights • This is the largest study reporting on leptomeningeal metastasis (LM) in EGFR -mutated NSCLC-patients. • Median survival of EGFR -mutated…”
Get full text

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective by Grit, Geeske F, van Geffen, Esmée, Malmberg, Ruben, van Leeuwen, Roelof, Böhringer, Stefan, JM Smit, Hans, Brocken, Pepijn, FH Eijsink, Job, Dronkers, Esther, Gal, Pim, Jaarsma, Eva, JHM van Drie-Pierik, Regine, MP Eldering-Heldens, Anne, Machteld Wymenga, AN, GM Mol, Peter, Zwaveling, Juliëtte, Hilarius, Doranne

“…•Alternative pembrolizumab dosing reduced median daily dose per patient by 22%.•We reported real-world data including overall survival in NSCLC…”
Get full text

Lung Cancer in the Netherlands by Hendriks, Lizza E L, Dingemans, Anne-Marie C, De Ruysscher, Dirk K M, Aarts, Mieke J, Barberio, Lidia, Cornelissen, Robin, Hartemink, Koen J, van den Heuvel, Michel, Schuuring, Ed, Smit, Hans J M, van der Wekken, Antonie J, Smit, Egbert F

Get more information

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study by Groen, Harry J. M., van der Heijden, Erik H. F. M., Klinkenberg, Theo J., Biesma, Bonne, Aerts, Joachim, Verhagen, Ad, Kloosterziel, Corinne, Pieterman, Remge, van den Borne, Ben, Smit, Hans J. M., Hoekstra, Otto, Schramel, Frans M. N. H., van der Noort, Vincent, van Tinteren, Harm, Smit, Egbert F., Dingemans, Anne-Marie C.

“…Background Retrospective studies suggest that low molecular weight heparin may delay the development of metastasis in patients with resected NSCLC. Methods…”
Get full text

Pneumonectomy for Lung Cancer Treatment in The Netherlands: Between-Hospital Variation and Outcomes by Beck, Naomi, van Brakel, Thomas J., Smit, Hans J. M., van Klaveren, David, Wouters, Michel W. J. M., Schreurs, Wilhelmina H.

“…Background Pneumonectomy in lung cancer treatment is associated with considerable morbidity and mortality. Its use is reserved only for patients in whom a…”
Get full text

Lessons learned from the Dutch Institute for Clinical Auditing: the Dutch model for quality assurance in lung cancer treatment by Beck, Naomi, Hoeijmakers, Fieke, Wiegman, Erwin M, Smit, Hans J M, Schramel, Franz M, Steup, Willem H, Verhagen, Ad F T M, Schreurs, Wilhelmina H, Wouters, Michel W J M

“…Quality registries play an important role in the professional quality system for cancer treatment in The Netherlands. This article provides insight into the…”
Get full text

Lung density measurements in spontaneous pneumothorax demonstrate airtrapping by Smit, Hans J M, Golding, Richard P, Schramel, Franz M N H, Devillé, Walter L, Manoliu, Radu A, Postmus, Pieter E

“…Idiopathic spontaneous pneumothorax (SP) is the result of leakage of air from the lung parenchyma through a ruptured visceral pleura into the pleural cavity…”
Get more information

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer by Mellema, Wouter W, Masen-Poos, Lucie, Smit, Egbert F, Hendriks, Lizza E.L, Aerts, Joachim G, Termeer, Arien, Goosens, Martijn J, Smit, Hans J.M, van den Heuvel, Michel M, van der Wekken, Anthonie J, Herder, Gerarda J.M, Krouwels, Frans H, Stigt, Jos A, van den Borne, Ben E.E.M, Haitjema, Tjeerd J, Staal-Van den Brekel, Agnes J, van Heemst, Robbert C, Pouw, Ellen, Dingemans, Anne-Marie C

“…Highlights • Subtypes of KRAS mutated NSCLC may respond differently to chemotherapy treatment. • Indeed, patients with G12V mutation had an improved response…”
Get full text